Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Cancer Research

Executive Summary: Anlotinib hydrochloride is a small-molecule, multi-target tyrosine kinase inhibitor that potently inhibits VEGFR2, PDGFRβ, and FGFR1 with IC₅₀ values in the 5.6–11.7 nM range ([APExBIO Product Dossier](https://www.apexbt.com/anlotinib-hydrochloride.html)). It demonstrates superior anti-angiogenic and anti-tumor efficacy compared to sunitinib and sorafenib ([Chen & Feng 2019, DOI:10.2147/OTT.S190333](http://dx.doi.org/10.2147/OTT.S190333)). The compound exhibits high oral bioavailability in animal models and favorable tissue distribution, including tumor and brain ([APExBIO Product Dossier](https://www.apexbt.com/anlotinib-hydrochloride.html)). Safety studies reveal a high LD₅₀ and minimal off-target toxicity at research concentrations. Anlotinib is recommended for mechanistic research in angiogenesis and tumor microenvironment workflows only, not for clinical or diagnostic use.

Biological Rationale

Angiogenesis is essential for tumor growth and metastasis. Inhibition of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRβ), and fibroblast growth factor receptor 1 (FGFR1) disrupts key signaling pathways that drive endothelial cell proliferation and migration. Anlotinib hydrochloride, provided by APExBIO, was developed to target these kinases with high specificity and potency, overcoming resistance and limited efficacy observed with earlier single-target inhibitors ([Chen & Feng 2019, DOI](http://dx.doi.org/10.2147/OTT.S190333)). Multi-target TKIs are now central to advanced tumor angiogenesis research, as they more comprehensively block redundant pro-angiogenic pathways ([GSKChem 2023](https://gskchem.com/index.php?g=Wap&m=Article&a=detail&id=11251)).

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride inhibits VEGFR2, PDGFRβ, and FGFR1 kinase domains, blocking downstream signaling via the ERK pathway. The compound prevents ligand-induced phosphorylation, suppressing endothelial cell migration and capillary tube formation in vitro. IC₅₀ values are as follows: VEGFR2: 5.6 ± 1.2 nM, PDGFRβ: 8.7 ± 3.4 nM, FGFR1: 11.7 ± 4.1 nM ([APExBIO Product Dossier](https://www.apexbt.com/anlotinib-hydrochloride.html)). Anlotinib also inhibits additional kinases such as c-Kit, Met, and FGFR4 at low nanomolar concentrations ([Chen & Feng 2019, DOI](http://dx.doi.org/10.2147/OTT.S190333)). The result is a broad-spectrum blockade of angiogenic and proliferative processes in tumor microenvironments. Importantly, anlotinib impairs signaling cascades downstream of these receptors, including the ERK and PI3K/AKT pathways, leading to reduced tumor cell survival and endothelial migration ([Molecular Beacon 2024](https://molecularbeacon.net/index.php?g=Wap&m=Article&a=detail&id=83)). This extends the utility of the compound beyond simple receptor inhibition and supports its application in multifaceted tumor biology assays.

Evidence & Benchmarks

• Anlotinib inhibits VEGFR2, PDGFRβ, and FGFR1 with IC₅₀ values of 5.6 ± 1.2 nM, 8.7 ± 3.4 nM, and 11.7 ± 4.1 nM, respectively (APExBIO Product Dossier: link).
• In cell-based assays, anlotinib blocks VEGF/PDGF-BB/FGF-2-induced endothelial cell migration and tube formation in a concentration-dependent manner (APExBIO Product Dossier: link).
• Compared to sunitinib, sorafenib, and nintedanib, anlotinib demonstrates greater inhibition of angiogenesis and tumor growth in xenograft models (Chen & Feng 2019, DOI).
• Oral bioavailability is 28–58% in rats and 41–77% in dogs, with high plasma protein binding (93%) in humans (APExBIO Product Dossier: link).
• Tissue distribution studies show high accumulation in lung, liver, kidney, heart, and tumor tissue, with blood-brain barrier penetration (APExBIO Product Dossier: link).
• Phase I/II clinical studies demonstrate anti-tumor activity in multiple solid tumor types, including desmoplastic small round cell tumors and non-small-cell lung cancer (Chen & Feng 2019, DOI).
• Safety studies report a median lethal dose (LD₅₀) of 1735.9 mg/kg in rats (14-day oral study), with no significant organ or genetic toxicity (APExBIO Product Dossier: link).

This article extends the comparative mechanistic context of Redefining Tumor Angiogenesis Inhibition by providing quantitative pharmacokinetic and safety data. It also updates the practical workflow recommendations from Anlotinib Hydrochloride: Advanced Workflows for Tumor Angiogenesis with new benchmarks for tissue distribution and bioavailability.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is widely used in preclinical research for:

• Endothelial cell migration and capillary tube formation assays.
• In vivo tumor angiogenesis and xenograft studies.
• Signaling pathway analysis, including ERK/PI3K-AKT.
• Comparative efficacy studies with other TKIs.

It is not approved for diagnostic or therapeutic use in humans; APExBIO supplies it for laboratory research only. Typical use cases involve human vascular endothelial cells (e.g., EA.hy 926) and animal models under controlled dosing and storage conditions ([APExBIO Product Dossier](https://www.apexbt.com/anlotinib-hydrochloride.html)).

Common Pitfalls or Misconceptions

• Not for clinical use: Anlotinib (hydrochloride) from APExBIO is strictly for research applications; it is not GMP-certified or approved for human administration.
• Assay specificity: Off-target effects may occur at higher concentrations; always use dose-response validation.
• Storage requirements: Compound must be stored at -20°C; deviations can reduce potency and reliability.
• Metabolic considerations: CYP3A-mediated metabolism may differ between species; extrapolation from rodent to human pharmacokinetics should be done with caution.
• Limited efficacy in non-angiogenesis models: Anlotinib is optimized for angiogenesis and tumor signaling studies, not for unrelated pathways or systemic toxicity tests.

Workflow Integration & Parameters

Anlotinib hydrochloride is compatible with a range of established cancer and angiogenesis research workflows. For in vitro assays, recommended concentrations typically range from 1 to 100 nM, depending on cell type and endpoint. In capillary tube formation assays, dose-dependent inhibition should be quantified using validated image analysis software. For in vivo xenograft studies, dosing regimens should be guided by published pharmacokinetic data, taking into account species-specific metabolism and oral bioavailability ([APExBIO Product Dossier](https://www.apexbt.com/anlotinib-hydrochloride.html)).

Researchers seeking advanced troubleshooting or comparative benchmarking can consult Anlotinib Hydrochloride: Precision Multi-Target Tyrosine Kinase Inhibitor, which details selectivity and reproducibility parameters. This article incorporates recent findings on tissue distribution and safety, providing a more comprehensive reference.

Conclusion & Outlook

Anlotinib hydrochloride, provided by APExBIO (SKU: C8688), offers robust multi-target inhibition of tyrosine kinases central to tumor angiogenesis and growth. Its favorable pharmacokinetics, broad tissue distribution, and superior efficacy position it as a reference molecule for cancer research workflows. Further studies are warranted to explore its combinatorial potential and to refine dosing strategies for translational research. Investigators are encouraged to reference the Anlotinib (hydrochloride) product page and linked protocols for up-to-date technical guidance.